PDB Short entry for 5HVP HEADER HYDROLASE/HYDROLASE INHIBITOR 30-APR-90 5HVP TITLE CRYSTALLOGRAPHIC ANALYSIS OF A COMPLEX BETWEEN HUMAN IMMUNODEFICIENCY TITLE 2 VIRUS TYPE 1 PROTEASE AND ACETYL-PEPSTATIN AT 2.0-ANGSTROMS TITLE 3 RESOLUTION COMPND MOL_ID: 1; COMPND 2 MOLECULE: HIV-1 PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 ENGINEERED: YES; COMPND 5 MOL_ID: 2; COMPND 6 MOLECULE: ACETYL-*PEPSTATIN; COMPND 7 CHAIN: C; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 6 EXPRESSION_SYSTEM_VECTOR_TYPE: BACTERIAL; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: STREPTOMYCES; SOURCE 9 ORGANISM_TAXID: 1883 KEYWDS ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR P.M.D.FITZGERALD,B.M.MCKEEVER,J.F.VANMIDDLESWORTH,J.P.SPRINGER REVDAT 5 29-NOV-17 5HVP 1 HELIX REVDAT 4 13-JUL-11 5HVP 1 VERSN REVDAT 3 24-FEB-09 5HVP 1 VERSN REVDAT 2 01-APR-03 5HVP 1 JRNL REVDAT 1 15-OCT-91 5HVP 0 JRNL AUTH P.M.FITZGERALD,B.M.MCKEEVER,J.F.VANMIDDLESWORTH, JRNL AUTH 2 J.P.SPRINGER,J.C.HEIMBACH,C.T.LEU,W.K.HERBER,R.A.DIXON, JRNL AUTH 3 P.L.DARKE JRNL TITL CRYSTALLOGRAPHIC ANALYSIS OF A COMPLEX BETWEEN HUMAN JRNL TITL 2 IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE AND ACETYL-PEPSTATIN JRNL TITL 3 AT 2.0-A RESOLUTION. JRNL REF J.BIOL.CHEM. V. 265 14209 1990 JRNL REFN ISSN 0021-9258 JRNL PMID 2201682 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH M.A.NAVIA,P.M.D.FITZGERALD,B.M.MCKEEVER,C.-T.LEU, REMARK 1 AUTH 2 J.C.HEIMBACH,W.K.HERBER,I.S.SIGAL,P.L.DARKE,J.P.SPRINGER REMARK 1 TITL THREE-DIMENSIONAL STRUCTURE OF ASPARTYL PROTEASE FROM HUMAN REMARK 1 TITL 2 IMMUNODEFICIENCY VIRUS HIV-1 REMARK 1 REF NATURE V. 337 615 1989 REMARK 1 REFN ISSN 0028-0836 REMARK 1 REFERENCE 2 REMARK 1 AUTH B.M.MCKEEVER,M.A.NAVIA,P.M.D.FITZGERALD,J.P.SPRINGER, REMARK 1 AUTH 2 C.-T.LEU,J.C.HEIMBACH,W.K.HERBER,I.S.SIGAL,P.L.DARKE REMARK 1 TITL CRYSTALLIZATION OF THE ASPARTYLPROTEASE FROM THE HUMAN REMARK 1 TITL 2 IMMUNODEFECIENCY VIRUS, HIV-1 REMARK 1 REF J.BIOL.CHEM. V. 264 1919 1989 REMARK 1 REFN ISSN 0021-9258 REMARK 1 REFERENCE 3 REMARK 1 AUTH P.L.DARKE,C.-T.LEU,L.J.DAVIS,J.C.HEIMABCH,R.E.DIEHL, REMARK 1 AUTH 2 W.S.HILL,R.A.F.DIXON,I.S.SIGAL REMARK 1 TITL HUMAN IMMUNODEFICIENCY VIRUS PROTEASE. BACTERIAL EXPRESSION REMARK 1 TITL 2 AND CHARACTERIZATION OF THE PURIFIED ASPARTIC PROTEASE REMARK 1 REF J.BIOL.CHEM. V. 264 2307 1989 REMARK 1 REFN ISSN 0021-9258 REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PROLSQ REMARK 3 AUTHORS : KONNERT,HENDRICKSON REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 8.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 12901 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 R VALUE (WORKING + TEST SET) : 0.176 REMARK 3 R VALUE (WORKING SET) : NULL REMARK 3 FREE R VALUE : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1550 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 2 REMARK 3 SOLVENT ATOMS : 170 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : 0.018 ; 0.020 REMARK 3 ANGLE DISTANCE (A) : 0.038 ; 0.030 REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : 0.043 ; 0.040 REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : 0.015 ; 0.020 REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : 0.177 ; 0.150 REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : 0.216 ; 0.500 REMARK 3 MULTIPLE TORSION (A) : 0.207 ; 0.500 REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : 0.245 ; 0.500 REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : 2.600 ; 3.000 REMARK 3 STAGGERED (DEGREES) : 17.400; 15.000 REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5HVP COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000179726. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : NULL REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : NULL REMARK 200 RADIATION SOURCE : NULL REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : NULL REMARK 200 WAVELENGTH OR RANGE (A) : NULL REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : NULL REMARK 200 DETECTOR MANUFACTURER : NULL REMARK 200 INTENSITY-INTEGRATION SOFTWARE : NULL REMARK 200 DATA SCALING SOFTWARE : NULL REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : NULL REMARK 200 RESOLUTION RANGE HIGH (A) : NULL REMARK 200 RESOLUTION RANGE LOW (A) : NULL REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : NULL REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 53.16 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.63 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 29.19500 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 43.35000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 29.19500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 43.35000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5570 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 8920 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -48.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 THE INHIBITOR BINDS TO THE ENZYME IN TWO ROUGHLY TWOFOLD REMARK 400 SYMMETRIC ORIENTATIONS. THE ALTERNATE CONFORMATIONS ARE REMARK 400 REPRESENTED BY THE ALTERNATE LOCATION INDICATORS *1* REMARK 400 AND *2*. THE FIRST ORIENTATION, *1*, WAS DENOTED A IN THE REMARK 400 PUBLICATION CITED IN THE *JRNL* RECORDS ABOVE, WHILE THE REMARK 400 ALTERNATE ORIENTATION, *2*, WAS DENOTED B. REMARK 400 REMARK 400 THE ACETYL-PEPSTATIN IS OLIGOPEPTIDE, A MEMBER OF INHIBITOR CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: ACETYL-PEPSTATIN REMARK 400 CHAIN: C REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 DESCRIPTION: NULL REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 41 CG CD NE CZ NH1 NH2 REMARK 470 LYS A 43 CG CD CE NZ REMARK 470 GLN A 61 CG CD OE1 NE2 REMARK 470 ILE A 72 CD1 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OD1 ASP A 25 OH STA C 4 1.99 REMARK 500 OD2 ASP A 30 OXT STA C 6 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 8 CD - NE - CZ ANGL. DEV. = -12.6 DEGREES REMARK 500 ARG A 8 NE - CZ - NH1 ANGL. DEV. = 3.4 DEGREES REMARK 500 ARG A 8 NE - CZ - NH2 ANGL. DEV. = -5.2 DEGREES REMARK 500 ASP A 29 CB - CG - OD1 ANGL. DEV. = -7.3 DEGREES REMARK 500 ASP A 30 CB - CG - OD2 ANGL. DEV. = -6.4 DEGREES REMARK 500 ARG A 57 NE - CZ - NH2 ANGL. DEV. = -4.1 DEGREES REMARK 500 ASP B 230 CB - CG - OD1 ANGL. DEV. = 9.3 DEGREES REMARK 500 ASP B 230 CB - CG - OD1 ANGL. DEV. = -5.7 DEGREES REMARK 500 ARG B 241 NE - CZ - NH2 ANGL. DEV. = -4.9 DEGREES REMARK 500 ASP B 260 CB - CG - OD2 ANGL. DEV. = -8.5 DEGREES REMARK 500 STA C 4 CA - C - N ANGL. DEV. = 19.2 DEGREES REMARK 500 STA C 4 CA - C - N ANGL. DEV. = 20.1 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLU A 35 123.35 -34.45 REMARK 500 GLU B 235 125.77 -36.70 REMARK 500 PRO B 279 95.24 -69.80 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 STA C 4 ALA C 5 -129.18 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 STA C 4 32.73 REMARK 500 STA C 4 33.44 REMARK 500 REMARK 500 REMARK: NULL REMARK 700 REMARK 700 SHEET REMARK 700 THE SHEET *S1* IS FORMED BY THE INTERDIGITATING STRANDS REMARK 700 FROM THE TWO MONOMERS OF THE DIMERIC ENZYME. STRANDS 1 AND REMARK 700 3 ARE FROM CHAIN *A*. STRANDS 2 AND 4 ARE FROM CHAIN *B*. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 343 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL B 336 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN C OF ACETYL-*PEPSTATIN REMARK 999 REMARK 999 SEQUENCE REMARK 999 IN THE PAPER CITED IN THE *JRNL* RECORDS ABOVE, THE *B* REMARK 999 CHAIN RESIDUES WERE NUMBERED FROM 201 TO 299. THIS REMARK 999 NUMBERING SCHEME HAS BEEN RETAINED. DBREF 5HVP A 1 99 UNP Q9WFL7 Q9WFL7_9HIV1 24 122 DBREF 5HVP B 201 299 UNP Q9WFL7 Q9WFL7_9HIV1 24 122 DBREF 5HVP C 1 6 PDB 5HVP 5HVP 1 6 SEQRES 1 A 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE SEQRES 2 A 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE LEU ILE GLU SEQRES 6 A 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP GLN ARG PRO LEU VAL THR ILE SEQRES 2 B 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL LEU GLU GLU MET ASN LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE LEU ILE GLU SEQRES 6 B 99 ILE CYS GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY CYS THR LEU ASN PHE SEQRES 1 C 6 ACE VAL VAL STA ALA STA HET ACE C 1 6 HET STA C 4 22 HET STA C 6 24 HET CL A 343 1 HET CL B 336 1 HETNAM ACE ACETYL GROUP HETNAM STA STATINE HETNAM CL CHLORIDE ION FORMUL 3 ACE C2 H4 O FORMUL 3 STA 2(C8 H17 N O3) FORMUL 4 CL 2(CL 1-) FORMUL 6 HOH *170(H2 O) HELIX 1 H1 ARG A 87 GLN A 92 1 6 HELIX 2 H2 ARG B 287 GLN B 292 1 6 SHEET 1 S1 4 PRO A 1 LEU A 5 0 SHEET 2 S1 4 CYS B 295 PHE B 299 -1 O LEU B 297 N ILE A 3 SHEET 3 S1 4 CYS A 95 PHE A 99 -1 O THR A 96 N ASN B 298 SHEET 4 S1 4 PRO B 201 LEU B 205 -1 O ILE B 203 N LEU A 97 SHEET 1 S2 2 VAL A 11 ILE A 15 0 SHEET 2 S2 2 GLN A 18 ALA A 22 -1 O ALA A 22 N VAL A 11 SHEET 1 S3 3 ALA A 22 LEU A 24 0 SHEET 2 S3 3 ASN A 83 GLY A 86 1 O ASN A 83 N LEU A 23 SHEET 3 S3 3 ASP A 30 VAL A 32 -1 N VAL A 32 O ILE A 84 SHEET 1 S4 2 LYS A 43 GLY A 49 0 SHEET 2 S4 2 GLY A 52 GLN A 58 -1 O GLN A 58 N LYS A 43 SHEET 1 S5 2 ILE A 62 ILE A 66 0 SHEET 2 S5 2 HIS A 69 GLY A 73 -1 N GLY A 73 O ILE A 62 SHEET 1 S6 2 VAL B 211 ILE B 215 0 SHEET 2 S6 2 GLN B 218 ALA B 222 -1 O ALA B 222 N VAL B 211 SHEET 1 S7 3 ALA B 222 LEU B 224 0 SHEET 2 S7 3 ASN B 283 GLY B 286 1 O ASN B 283 N LEU B 223 SHEET 3 S7 3 ASP B 230 VAL B 232 -1 N VAL B 232 O ILE B 284 SHEET 1 S8 2 LYS B 243 GLY B 249 0 SHEET 2 S8 2 GLY B 252 GLN B 258 -1 O GLN B 258 N LYS B 243 SHEET 1 S9 2 ILE B 262 ILE B 266 0 SHEET 2 S9 2 HIS B 269 GLY B 273 -1 N GLY B 273 O ILE B 262 LINK C AVAL C 3 N ASTA C 4 1555 1555 1.38 LINK C BVAL C 3 N BSTA C 4 1555 1555 1.34 LINK C ASTA C 4 N AALA C 5 1555 1555 1.34 LINK C BSTA C 4 N BALA C 5 1555 1555 1.34 LINK C AALA C 5 N ASTA C 6 1555 1555 1.34 LINK C BALA C 5 N BSTA C 6 1555 1555 1.35 SITE 1 AC1 2 THR A 74 ASN A 88 SITE 1 AC2 4 GLY B 273 THR B 274 ASN B 288 HOH B 356 SITE 1 AC3 30 ARG A 8 ASP A 25 GLY A 27 ALA A 28 SITE 2 AC3 30 ASP A 29 ASP A 30 LYS A 45 ILE A 47 SITE 3 AC3 30 GLY A 48 GLY A 49 ILE A 50 VAL A 82 SITE 4 AC3 30 ILE A 84 ARG B 208 LEU B 223 ASP B 225 SITE 5 AC3 30 GLY B 227 ALA B 228 ASP B 229 ASP B 230 SITE 6 AC3 30 LYS B 245 ILE B 247 GLY B 248 GLY B 249 SITE 7 AC3 30 ILE B 250 ILE B 284 HOH B 319 HOH C 308 SITE 8 AC3 30 HOH C 311 HOH C 417 CRYST1 58.390 86.700 46.270 90.00 90.00 90.00 P 21 21 2 8 ORIGX1 0.017126 0.000000 0.000000 0.00000 ORIGX2 0.000000 0.011534 0.000000 0.00000 ORIGX3 0.000000 0.000000 0.021612 0.00000 SCALE1 0.017126 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011534 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021612 0.00000